Académique Documents
Professionnel Documents
Culture Documents
n e w e ng l a n d j o u r na l
of
m e dic i n e
283
The
n e w e ng l a n d j o u r na l
M. tuberculosis
IgA
Lu et al.
study
IgG
Active tuberculosis
Zimmermann
et al. study
M. tuberculosis
M. tuberculosis
IgG
Macrophage
Epithelial cell
m e dic i n e
Latent tuberculosis
Zimmermann
et al. study
of
Lu et al.
study
IgG
M. tuberculosis
Macrophage
Epithelial cell
M. tuberculosis replicates
in macrophages
284
nejm.org
negative results in the historical attempts to establish a role for antibody immunity were possibly false and stemmed from the functional
variation in antibody responses to M. tuberculosis,
rather than from an inherent limitation in humoral immunity to protect against this pathogen.
The discovery of functional differences in the
efficacy of antibodies to M. tuberculosis could have
substantial clinical implications if developed
further in subsequent studies. If the functional
differences between antibodies in persons with
latent tuberculosis and the antibodies in those
with active tuberculosis are shown to have a
cause and effect, it may be possible to use serologic testing to identify persons at risk for disease. For example, the identification of persons
with effective antibody responses could allow
the stratification of infected persons such that
only those with nonprotective antibody responses
are given prophylaxis. In the prechemotherapy
era, it was known that a considerable proportion
of persons with pulmonary tuberculosis either
healed or had stabilized disease. If these different outcomes were associated with differences
in humoral immune responses, serologic testing
could also provide prognostic information that
could help improve therapy. If these findings are
replicated and a cause-and-effect relationship is
determined, they are likely to stimulate the search
for new vaccines that prevent tuberculosis by eliciting antibody responses that promote latency or
the elimination of infection.
rial antigens in children with tuberculosis: challenges and potential diagnostic value. Clin Vaccine Immunol 2012;19:1898-906.
2. Glatman-Freedman A, Casadevall A. Serum therapy for tuberculosis revisited: reappraisal of the role of antibody-mediated
immunity against Mycobacterium tuberculosis. Clin Microbiol
Rev 1998;11:514-32.
3. Achkar JM, Chan J, Casadevall A. B cells and antibodies in
the defense against Mycobacterium tuberculosis infection. Immunol Rev 2015;264:167-81.
4. Lu LL, Chung AW, Rosebrock TR, et al. A functional role for
antibodies in tuberculosis. Cell 2016;167(2):433-443.e14.
5. Zimmermann N, Thormann V, Hu B, et al. Human isotypedependent inhibitory antibody responses against Mycobacterium
tuberculosis. EMBO Mol Med 2016;8:1325-39.
DOI: 10.1056/NEJMcibr1613268
Copyright 2017 Massachusetts Medical Society.
285